{'fraction_non_alphanumeric': 0.03015873015873016, 'fraction_numerical': 0.031746031746031744, 'mean_word_length': 4.842592592592593, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
The use of plerixafor in harvesting autologous stem cells in the pediatric setting

The mobilization of stem cells using the standard approach, chemotherapy and G‐CSF, may not be successful in all cases heavily pretreated. Plerixafor (AMD3100) has emerged as a viable option in attempts to mobilize stem cells among these patients. The use of plerixafor in the adult setting has been established, but data on pediatric use is scarce. We report on the use of plerixafor in eight pediatric cases either as add‐on to chemotherapy plus G‐CSF or in remobilization. Pediatr Blood Cancer 2012; 59: 197–198. © 2011 Wiley Periodicals, Inc.